蛋白质药物的研究现状资料.doc

蛋白质药物的研究现状郭世江 20123762 制药二班摘要: 蛋白质药物可分为多肽和基因工程药物、单克隆抗体和基因工程抗体、重组疫苗; 本文主要着重讲解多肽和基因工程药物。与以往的小分子药物相比,蛋白质药物具有高活性、特异性强、低毒性、生物功能明确、有利于临床应用的特点。由于其成本低、成功率高、安全可靠, 已成为医药产品中的重要组成部分。 1982 年美国 Likky 公司首先将重组胰岛素投放市场, 标志着第一个重组蛋白质药物的诞生。一种新型生物技术候选药物, 它具有高效抗肿瘤、抗病毒功能。经中国药品生物制品标准化研究中心检测证实, 其抗肿瘤活性较同类产品高 倍,抗病毒活性高 10 倍以上, 可用于治疗多种恶性肿瘤和病毒感染性疾病。关键词: 多肽, 基因工程药物, 单克隆抗体, 基因工程抗体, 重组疫苗, 高活性,低毒性, 抗肿瘤, 抗病毒。 Abstract :Polypeptide and protein drugs can be divided into ic engineering drugs, monoclonal antibodies and ically engineered antibodies, binant ine; paper mainly focuses on explaining polypeptides and ic engineering drugs. Compared with conventional small molecule drugs, protein drugs with high activity and specificity, low toxicity, biological features a clear, beneficial characteristics of clinical applications. Because of its low cost, high ess rate, safe and reliable pharmaceutical products has e an important part. 1982 United States pany first binant insulin market, marking the birth of the first binant protein drugs. A new biotech drug candidates, it is an efficient anti-tumor, anti-viral function. By the China Research Center of Pharmaceutical and Biological Products Standardization tests confirmed that the anti-tumor activity of times higher than similar products, high antiviral activity more than 10 times, can be used to treat a variety of malignancies and viral infections. Keywords: Pe